Abstract submission

This topic explores how radiologists can extract additional, clinically-relevant information from routine imaging studies performed for other indications, such as: 

• Body composition 
• Assessing bone mineral density 
• Identifying coronary artery calcifications on CT  

By leveraging data in existing imaging, opportunistic screening represents a potentially cost effective and data-rich avenue for early disease detection to optimize population health. New results at large scale, exploration of issues of clinical acceptance and biomarker validation are some examples of topics of interest within this arena. 

Focusing on the dynamic interface between scientific discovery and clinical application, this topic highlights research that results from collaboration between radiologists and industry.  
 
Submissions may include:  

• Co-development and real-world deployment of AI applications, including:  
• Diagnostic support tools 
• Workflow optimization platforms 
• Imaging triage systems 
• Advances in imaging hardware and software 

Emphasis is placed on novelty, regulatory navigation, clinical validation, integration into radiology workflows, post-deployment monitoring and measurable impact on patient care. 

This topic addresses innovative imaging methods that minimize or eliminate the need for exogenous contrast, including: 

• Development of novel sequences 
• Clinical implementation 
• Comparative effectiveness 
• Cost analysis 
• Environmental benefits 
• Safety 
• Diagnostic efficacy 

This topic examines the frontier of imaging-enabled cancer therapies, including non-invasive ablation techniques like histotripsy and molecularly-targeted agents used in theranostics.  
 
Emphasis is placed on how radiologists are central to both the diagnostic and therapeutic continuum in precision oncology through image-guided delivery and response assessment. 

This abstract call is intended for high-impact imaging clinical trials based on late-breaking data (after May 7, 2025). Accepted abstracts will be featured in dedicated sessions at RSNA 2025. 

Abstracts must meet the following criteria: 

• Prospective study design 
• Conducted across multiple centers 
• Centered on radiology or medical imaging 
• Demonstrate clear potential to impact clinical practice 
• Include data/outcomes collected after May 7, 2025 
• Not submitted during the spring RSNA 2025 call for abstracts 

Abstracts may be presented at a non-imaging scientific meeting in the same calendar year or later. 

Hypothesis-driven research that may be submitted as a paper to be presented orally or as a digital presentation.

Education exhibits should be designed to teach or review topics related to medical imaging. They may be presented as digital presentations or standalone exhibits.

A presentation of quality assessment and improvement initiatives aimed at improving patient care in radiology. Reports will be presented as digital presentations and all require an oral presentation.

A $3,000 prize awarded to the top scientific paper in neuroradiology as selected by the Annual Meeting Program Planning Committee.

A $1,000 prize is awarded to an outstanding scientific presentation in each subspecialty presented by a resident, fellow, medical student or physics trainee.

All eligible education exhibits are reviewed by the Education Exhibits Awards Committee appointed by the board of directors and awards are announced at the annual meeting.

All eligible quality improvement report exhibits are reviewed and awards are announced at the annual meeting.

All eligible scientific posters are reviewed and awards are announced at the annual meeting.

The requirement for financial disclosure from committee members, planners, reviewers, authors, and presenters is a mandatory element in maintaining ACCME accreditation for all organizations that provide continuing education (CE) activities. If an individual refuses to disclose, he/she will not be permitted to participate as a planner, committee member, reviewer, author, or presenter.

As an ACCME-accredited provider, the RSNA must ensure that education is fair and balanced and that any clinical content presented supports safe, effective patient care. The ACCME defines ineligible companies as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients." 

Further, the provider must be able to show that individuals in a position to control the content of an education activity, including committee members, reviewers, planners, authors, and presenters, has disclosed all financial relationships with ineligible companies to the provider. Individuals in a position to control the content must disclose regardless of their view of the relevance of the relationship to the education. The provider must identify, mitigate, and disclose all identified financial relationships to an education activity being delivered to the learners.

If you have or have had within the previous 24 months such a relationship or affiliation, you must disclose this information. Likewise, disclosure that no relationship(s) exists is also required. The intent of this policy is not to prevent an individual with a financial relationship from participating; however, in accordance with ACCME standards, the RSNA has developed policies and procedures to manage identified financial relationships.